RESUMEN
This study was designed to investigate the susceptibility of liver and brain tissues, as insulinin-dependent tissues, of normal adult male rats to the oxidative challenge of subchronic supplementation with chromium picolinate (CrPic) at low (human equivalent) and high doses (2.90 and 13.20 µg Cr kg(-1) day(-1), respectively). Also, the modulative effect of CrPic administration on the enhanced oxidative stress in the liver and brain tissues of alloxan-diabetic rats was studied. Fasting serum glucose level was not modified in normal rats but significantly reduced in diabetic rats that had received CrPic supplement. A mild oxidative stress was observed in the liver and brain of CrPic-supplemented normal rats confirmed by the dose-dependent reductions in the levels of hepatic and cerebral free fatty acids, superoxide dismutase and glutathione peroxidase activities, and in contrast increased tissue malondialdehyde concentration. On the other hand, hepatic and cerebral catalase activity was reduced in the high dose group only. CrPic supplementation did not act as a peroxisome proliferator confirmed by the significant reductions in liver and brain peroxisomal palmitoyl CoA oxidase activity. The non significant alterations in liver protein/DNA and RNA/DNA ratios indicate that CrPic did not affect protein synthesis per cell, and that mild elevations in hepatic total protein and RNA concentrations might be due to block or decrease in the export rate of synthesized proteins from the liver to the plasma. In diabetic rats, elevated levels of hepatic and cerebral free fatty acids and malondialdehyde, and in contrast the overwhelmed antioxidant enzymes, were significantly modulated in the low dose group and near-normalized in the high dose group. The significant increases observed in liver total protein and RNA concentrations, as well as protein/DNA and RNA/ DNA ratios in diabetic rats supplemented with the high dose of Cr, compared to untreated diabetics, may be related to the improvement in the glycemic status of the diabetic animals rather than the direct effect of CrPic on protein anabolism.
Asunto(s)
Cromo/farmacología , Diabetes Mellitus Experimental/metabolismo , Aloxano/toxicidad , Animales , Encéfalo/metabolismo , Catalasa/metabolismo , Cromo/metabolismo , ADN/análisis , Diabetes Mellitus/metabolismo , Diabetes Mellitus Experimental/inducido químicamente , Diabetes Mellitus Experimental/fisiopatología , Modelos Animales de Enfermedad , Glutatión Peroxidasa/metabolismo , Índice Glucémico , Humanos , Peroxidación de Lípido/efectos de los fármacos , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Malondialdehído/análisis , Estrés Oxidativo/efectos de los fármacos , Oxidorreductasas/metabolismo , Ácidos Picolínicos/metabolismo , Ácidos Picolínicos/farmacología , ARN/análisis , Ratas , Ratas Wistar , Superóxido Dismutasa/metabolismoRESUMEN
The effects of leuprorelin acetate, a luteinizing hormone-releasing hormone agonist (LHRH-A), on prostate carcinogenesis in probasin/SV40 Tag transgenic rat was investigated. Fifteen weeks after administration of 0.28 and 2.8 mg/kg leuprorelin, prostate weights and serum testosterone levels were significantly decreased compared to values for transgenic controls. Histopathological findings revealed that the incidence of prostatic adenocarcinomas was significantly reduced in ventral, dorsal and lateral lobes of the prostate, correlating with decreased expression of SV40 Tag oncoprotein as well as inhibition of DNA synthesis and proliferation of epithelial cells in neoplastic lesions of the ventral prostate. Microarray analysis further showed leuprorelin acetate to significantly inhibit testicular steroidogenesis, suppressing the expression of SV40 Tag oncoprotein and altering the expression of a large number of genes which might be involved in the inhibition of prostate cancer progression in this rat model.
Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Antineoplásicos Hormonales/farmacología , Leuprolida/farmacología , Neoplasias de la Próstata/tratamiento farmacológico , Adenocarcinoma/genética , Proteína de Unión a Andrógenos/genética , Animales , Animales Modificados Genéticamente , Antígenos Transformadores de Poliomavirus/genética , Hormona Folículo Estimulante/sangre , Hormona Liberadora de Gonadotropina/agonistas , Inmunohistoquímica , Hormona Luteinizante/sangre , Hormona Luteinizante/efectos de los fármacos , Masculino , Análisis de Secuencia por Matrices de Oligonucleótidos , Próstata/efectos de los fármacos , Neoplasias de la Próstata/genética , ARN Mensajero/análisis , Ratas , Receptores Androgénicos/efectos de los fármacos , Receptores Androgénicos/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Vesículas Seminales/efectos de los fármacos , Testosterona/sangreRESUMEN
In the present study, the effects of subchronic treatments (4 weeks) of hypercholesterolemic (single) and diabetic-hypercholesterolemic (combined) rats with 4 (3H) quinazolinone and 2 halogenated derivatives (6, 8-dibromo-2-methy-4 (3H) quinazolinone and 6-iodo-2-methyl-4(3H) quinazolinone) at a sublethal dose level (2 mg/Kg) on cholesterol metabolism were investigated. Bezafibrate, a hypolipidemic drug was used as a reference compound for data comparison. Treatment of rats with single and combined hypercholesterolemia with quinazolinone compounds gave rise to highly significant reductions in serum total cholesterol and cholesterol ester levels, whereas serum triacylglycerol level was significantly reduced only after treatment with halogen-substituted quinazolinones in single hyper-cholesterolemia, compared to the control group. The effects of different quinazolinones and bezafibrate on reduction of serum LDL-C level were comparable in single hypercholesterolemia but significantly different in combined hypercholesterolemia. Results obtained from this study suggest that the antihyperlipidemic effect of quinazolinone compounds was brought about by inhibition of dietary cholesterol absorption and / or intestinal ACAT activity.
Asunto(s)
Hipolipemiantes/farmacología , Quinazolinas/farmacología , Animales , Bezafibrato/uso terapéutico , Glucemia/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Colesterol en la Dieta/administración & dosificación , Diabetes Mellitus Experimental/sangre , Hipercolesterolemia/sangre , Hipercolesterolemia/tratamiento farmacológico , Lípidos/sangre , Masculino , Malondialdehído/metabolismo , Quinazolinonas , RatasRESUMEN
In the present study chemical inactivation of bovine viral diarrhea virus (BVDV), as a substitute of hepatitis C virus was studied in human plasma pool. Beta-propiolactone (BPL), binary ethyleneimine (BEI) and chlorhexidine (CHX) were assessed. Treatment of virus-spiked human plasma with 0.025% BPL reduced virus infectivity titer to undetectable levels within 2 h, whereas BEI treatment (1 mM) showed a slower kinetic of inactivation, attaining a complete virus inactivation within 8 h of incubation. In contrast, CHX treatment at the adopted dose level (0.41mM) showed a limited virucidal capacity with a residual live virus titer after 24 h. BPL and BEI treatments reduced the recovery of labile plasma coagulation factors activity (V and VIII), while the activity of other coagulation factors (VII, IX and XI) was mildly decreased. Agarose gel electrophoresis of plasma proteins showed that albumin concentration is not affected, while gamma-globulin is slightly reduced by BPL and BEI treatment. Plasma fibrinogen level was modestly reduced by BPL treatment, while it remained unchanged by BEI treatment. This demonstrates the potential and safety use of BPL and BEI in BVDV inactivation in human plasma pool without affecting significantly the coagulant activity of important blood coagulation factors and the levels of plasma major protein fractions.
Asunto(s)
Aziridinas/farmacología , Proteínas Sanguíneas/análisis , Virus de la Diarrea Viral Bovina/efectos de los fármacos , Plasma/química , Propiolactona/farmacología , Inactivación de Virus/efectos de los fármacos , Animales , Antivirales/farmacología , Aziridinas/toxicidad , Factores de Coagulación Sanguínea/análisis , Bovinos , Línea Celular , Clorhexidina/farmacología , Clorhexidina/toxicidad , Electroforesis en Gel de Poliacrilamida , Humanos , Dosificación Letal Mediana , Masculino , Ratones , Plasma/efectos de los fármacos , Plasma/virologíaRESUMEN
In the present study the chemopreventive activities of DFMO, the irreversible inhibitor of ornithine decarboxylase, and finasteride, the inhibitor of prostatic 5a-reductase, against the development of chemically induced prostate adenocarcinoma by methylnitrosourea/testosterone propionate in male Wistar rats were investigated. According to histological examination, oral administration of DFMO and finasteride, either alone or combined, for two months to MNU/TP-inoculated rats reduced the tumor incidence to 11.11%, 10% and 10%, respectively, compared to tumored controls (64.3%). DFMO and/or finasteride treatment resulted in significant reductions in the wet weight of the prostate gland and seminal vesicles and its ratio relative to the total body weight, as well as the levels of prostate total protein, DNA, RNA and DNA/RNA ratio, compared to tumored controls. However, the effect of the combined treatment was of no statistical significance compared to single DFMO or finasteride treatment, as demonstrated by the non-significant differences between the mean values of most of the studied parameters. The tumor chemopreventive activity and the prostate growth inhibitory effect of DFMO and finasteride were due to suppression of prostate polyamine synthesis. ANOVA test revealed that the relative weight of the prostate as well as blood and tissue polyamine levels could be used as significant endpoint biomarkers for DFMO and finasteride as cancer chemopreventive agents.